With these latest approvals, Health Canada has now approved KSM-66 for a total of 14 claims, according to a press release from Ixoreal. Issuance of an NPN means the governmental regulatory body in Canada has reviewed the ingredient and its clinical evidence, and determined it be safe, effective, and of high quality under their recommended conditions of use, the release explains. Information on the clinical science supporting KSM-66 is availablehere.
“We are very pleased with these new set of claims,” said Kartikeya Baldwa, CEO at KSM-66 Ashwagandha. "These health claims are a testament to high-quality clinical research backing KSM-66, which Health Canada has recognized. We thank our partner CK Nutraceuticals for their continued strong performance in the Canadian market with respect to KSM-66’s market development."